Marx F J, Staehler G, Faul P, Schramm W
Urologe A. 1975 May;14(3):127-31.
70 nonselcted patients with prostatic carcinoma underwent coagulation analysis. Sxi had typical evidence of diffuse intravascular coagulation and in 8 cases such a disorder was highly probable. In 3 patients coagulation alterations appeared only after estrogen treatment, 17 patients (24.3%) thus showed evidence of intravascular coagulation. The hemostatic distrubance was silent in all but 3 cases where bleeding occurred. Coagulation disorders were found mainly in advanced stages and poorly differentiated carcinomas. There was a much higher content of thromboplastic activity in prostatic carcinoma than in normal prostatic tissue. Heparin plays a predominant role in the treatment of the coagulation disorder. In addition to therapy of clinically maifest consuption coagulopathy heparin can be used in prophylaxis against bleeding and thrombosis in cases with clinically silent intravascular coagulation and also in estrogen treatment.
70例未经选择的前列腺癌患者接受了凝血分析。6例有弥散性血管内凝血的典型证据，8例极有可能存在这种病症。3例患者仅在雌激素治疗后出现凝血改变，17例患者（24.3%）因此有血管内凝血的证据。除3例发生出血外，所有患者的止血障碍均无明显症状。凝血障碍主要见于晚期和低分化癌。前列腺癌组织中的促凝活性含量远高于正常前列腺组织。肝素在凝血障碍的治疗中起主要作用。除了对临床明显的消耗性凝血病进行治疗外，肝素还可用于预防临床无症状的血管内凝血患者的出血和血栓形成，以及用于雌激素治疗。
